H.C. Wainwright Reiterates Buy Rating, $13 Price Target on IMV (IMV), "AACR Results Add Confidence to DPX-Based Therapies in Bladder Cancer and Beyond"
Tweet Send to a Friend
H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating and $13.00 price target on IMV Inc. (NASDAQ: IMV), following the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
